ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Infectious Diseases
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1681624
Duration of immunity against infectious rhinotracheitis and bovine viral diarrhea after vaccination in calves in southern region of Kazakhstan
Provisionally accepted- 1Laboratory for Technologies of Cultivation of Microorganisms, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
- 2Laboratory for Control of Technologies and Biopreparations, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
- 3Laboratory for Collection of Microorganisms, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
- 4Laboratory for Technologies of Finished Forms of Biological Preparations, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
- 5Laboratory for Monitoring of Infectious Diseases, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
- 6National Holding “QazBioPharm”, Astana, Kazakhstan
- 7Department of Biological Safety, Faculty of Veterinary and Zooengineering, Kazakh National Agrarian Research University, Almaty, Kazakhstan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Some of the most economically significant viral infections affecting cattle globally include infectious bovine rhinotracheitis (IBR) and bovine viral diarrhea (BVD). Both viruses cause a wide range of clinical consequences and significant economic losses. Recent serological surveillance in Kazakhstan showed that these infections persist despite commercial vaccines, underscoring the need for more effective, locally appropriate immunization protocols. This study aimed to evaluate the duration of immunity conferred by a developed associated inactivated emulsion vaccine against IBR (strain “R-93”) and BVD (strain “Oregon C24V”), produced by the Research Institute for Biological Safety Problems. In the southern region of Kazakhstan. Of the twelve seronegative for BoHV-1 and BVDV clinically healthy crossbred calves (Friesian-Holstein and Kazakh Whiteheaded) eight were vaccinated, revaccinated, and monitored over a 9-month period for evaluation of the vaccine. Humoral immune responses were assessed using enzyme-linked immunosorbent assay and virus neutralization assays. Specific antibodies to BoHV-1 and BVDV were detected as early as day 7 post-vaccination, with titers peaking at 6.16 log₂ and 6.24 log₂, respectively, by day 28, and remaining above protective levels for at least six months. At nine months, a challenge was conducted using virulent strains: no clinical signs or lesions in vaccinated animals, fever and respiratory systems in unvaccinated animals. These findings suggest that the tested inactivated vaccine is safe, immunogenic, and capable of providing sustained protection in crossbred cattle under local climatic conditions. Although the sample size was limited, the results allow us to make preliminary conclusions about the vaccine’s efficacy; however, further large-scale studies are needed.
Keywords: infectious bovine rhinotracheitis1, bovine viral diarrhea2, Vaccine3, prevention4, calves5, immunity6
Received: 07 Aug 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 Bulatov, Sametova, Abitayev, Kyrgyzbayeva, Ussembay, Kondibaeva, Zhanat, Turyskeldy, Toktyrova, Mazbayeva, Shorayeva, Jekebekov, Zhugunissov, Barakbayev, Kerimbayev, Rsaliyev, Abduraimov and Kurmasheva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yerbol Bulatov, Laboratory for Technologies of Cultivation of Microorganisms, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
Alina Kurmasheva, Laboratory for Technologies of Cultivation of Microorganisms, Research Institute for Biological Safety Problems National holding “QazBioPharm”, Guardeyskiy, Kazakhstan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.